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Background:  The aim of this study was to investigate the effects of preoperative statin therapy on myocardial 
protection and morbidity endpoints following off-pump coronary bypass graft surgery (OPCAB) in patients with 
elevated serum high-sensitivity C-reactive protein (hs-CRP) levels.
Methods:  Of the 492 patients who underwent multivessel OPCAB from March 2007 to February 2009, the records 
of 144 patients whose baseline hs-CRP level > 2 mg/L were reviewed. According to the history of preoperative 
statin therapy for at least one week, patients were classified as either statin group or control group (72 subjects 
each).  Preoperative and operative characteristics and postoperative data including troponin (Tn)–T level and major 
morbidity endpoints were obtained and compared.  Major morbidity endpoints were defined as permanent stroke, 
renal dysfunction, hemostatic re-exploration, deep sternal wound infection, and the number of patients requiring 
prolonged ventilation.
Results:  Preoperative and operative characteristics were similar between the two groups.  There were no significant 
differences in the incidence of morbidity endpoints between the two groups, except for the number of patients 
requiring dialysis, which was significantly lower in the statin group (8 vs. 1, P = 0.033).  Tn–T level at 24 h after surgery 
was also significantly lower in the statin group. 
Conclusions:  In this study, we observed beneficial effects of preoperative statin therapy for at least one week in 
terms of less myocardial enzyme release and fewer patients requiring dialysis following OPCAB in patients whose 
preoperative hs-CRP was elevated.  (Korean J Anesthesiol 2010; 58: 136-141)
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Introduction
    Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitor) exert multiple beneficial effects in terms of preventing 
cardiovascular events, including cardiac death, myocardial 
infarction (MI), stroke, and renal dysfunction, in patients un-
der  going percutaneous coronary intervention or with peri-
pheral arterial disease [1-3]. These effects are attributable to 
both the lipid-lowering effect and pleiotropic effects beyond 
lipid lowering, such as anti-thrombotic and anti-inflammatory 
effects [4-6]. Consequently, statin therapy is commonly recom-
mended for high-risk patients with normal average cholesterol 
levels as well as for those with hypercholesterolemia for the 
primary prevention of acute coronary events [7,8].
    Despite the well-established beneficial role of statin therapy, 
conflicting results have been reported with regard to myocardial 
protection or the prevention of major morbidity endpoints 
following coronary artery bypass graft surgery (CABG) [9-15]. 
A recent JUPITER trial revealed beneficial effects of stains on 
reduction of major cardiovascular events in healthy patients 
with elevated high-sensitivity C-reactive protein (hs-CRP) levels 
[16]. The hs-CRP is a well-known marker of inflammatory status 
and is a reliable prognostic factor following CABG [17-19], and 
has already been used as an index of targeting statin therapy for 
prevention of coronary events [20,21]. Thus, it is reasonable to 
assume that patients with elevated hs-CRP would benefit most 
from statin therapy even in the surgical setting.
    However, evidence is limited in terms of the effect of statin 
therapy on myocardial protection and morbidity endpoints in 
patients with elevated hs-CRP undergoing CABG. With regard 
to assessing the myocardial protective effect, multi-vessel off-
pump CABG provides an optimal model for the presence of 
cumulative myocardial ischemia-reperfusion injury.
    Therefore, the aim of the present study was to investigate the 
effects of preoperative statin therapy on myocardial protection 
and morbidity endpoints following off-pump CABG in patients 
with elevated hs-CRP. 
Materials and Methods
    A total of 492 electronic medical charts of patients who 
underwent elective isolated multi-vessel off-pump CABG from 
March 2007 to February 2009 were retrospectively reviewed. 
After excluding patients who were enrolled in other clinical 
studies and selecting 178 patients with baseline hs-CRP ≥ 2 
mg/L according to the JUPITER trial [16], further selection was 
done for patients who received any kind of statin therapy for at 
least one week (statin group) or no statin therapy at all (control 
group). This retrieved a total of 144 patients, with 72 patients in 
each group. Of the 72 patients in the statin group, 25 received 
atorvastatin (10–30 mg/d), 18 received rosuvastatin (10–40 
mg/d), 16 received simvastatin (10–40 mg/d), and 13 received 
pravastatin (10–40 mg/d). 
    All patients received standardized anesthetic and surgical care 
according to institutional guidelines as follows. They received 
0.05–0.1 mg/kg of morphine intramuscularly as premedication 
1 h before operation. Upon arrival at the operating room, 
standard monitoring devices were applied, including a pul-
mo  nary artery catheter (PAC, Swan-Ganz CCOmbo CCO/
SvO2
TM, Edwards Lifesciences LLC, Irvine, CA, USA), which 
was inserted via the right internal jugular vein and connected 
to an analysis system (Vigilance
TM, Edwards Lifesciences LLC, 
Irvine, CA, USA) for continuous monitoring of cardiac index (CI) 
and mixed venous oxygen saturation (SvO2). Anesthesia was 
induced with intravenous midazolam (0.03-0.07 mg/kg) and 
sufentanil (1.5–2.0 μg/kg), and maintained with sevoflurane 
(0.8-1.5%) and continuous infusion of sufentanil (0.5-1.5 μg/
kg/h). Neuromuscular blockade was achieved by administering 
rocuronium (0.9 mg/kg) and maintained with continuous 
infusion of vecuronium (1-2 μg/kg/min). Isosorbide dinitrate 
0.5 μg/kg/min was infused in all patients throughout the study 
period. The patients’ lungs were ventilated with a tidal volume 
of 8-10 ml/kg, I : E ratio of 1 : 2, at a rate of 8-12 breaths/min 
with 40% oxygen in air and positive end-expiratory pressure of 
5 cmH2O during the surgery. After induction of anesthesia, a 
transesophageal echocardiography probe was inserted to assess 
global cardiac function and detect newly developing segmental 
wall motion abnormalities. Intravascular volume replacement 
was managed with crystalloid and colloid solutions to maintain 
the pulmonary capillary wedge pressure between 8 and 16 
mmHg, according to the baseline values. During the period 
of heart displacement, crystalloid solution was infused at a 
fixed rate of 6-8 ml/kg, whereas colloid solution was infused 
to compensate for the amount of blood loss collected by a cell 
salvage device. The salvaged blood by the cell salvage device 
was rein fused into the patient before the end of the surgery. 
Hemodynamic management during the period of heart 
displacement and grafting was as follows: 1) maintenance of 
mean systemic arterial pressure above 70 mmHg either with 10–
20
o Trendelenburg position and/or norepinephrine infusion; 
2) infusion of milrinone in patients with SvO2 < 60% for longer 
than 10 min and/or development of mitral regurgitation ≥ grade 
3 with concomitant rise in mean pulmonary arterial pressure 
>30 mmHg. Allogenic packed red blood cells were transfused 
when the hematocrit level was <25% throughout the study 
period. Central temperature measured by PAC was maintained 
above 36
oC with a warm mattress, forced warm-air blanket, and 
fluid warmer as necessary.
    All surgical procedures were performed by one surgeon 
through a median sternotomy, and the heart was displaced 138 www.ekja.org
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using posterior pericardial stitch, large (12 × 70 cm) gauze 
swabs, and tissue stabilizer (Rosta
Ⓡ 2.0, Yoorim Corporation, 
Chungbuk, Korea). The sequence of grafting was always the left 
internal mammary artery to left anterior descending coronary 
artery (LAD) first, followed by grafting on the circumflex 
coronary artery and the right coronary artery (RCA) by way 
of composite Y graft consisting of radial artery or saphenous 
vein with left internal mammary artery and/or by use of right 
internal mammary artery as necessary. An intracoronary shunt 
was used during grafting procedures on the LAD and distal 
RCA. All patients were transferred to the intensive care unit 
(ICU) after surgery.
    Assessed preoperative data included demographic data, 
serum creatinine (Cr) level, troponin (Tn)–T level, cardiac 
medications, and presence of diabetes mellitus, hypertension, 
chronic renal failure, recent MI (within one month), left main 
disease, and the percentage of stenosis of the coronary arteries. 
Assessed operative data included duration of surgery, number 
of grafts performed, and graft reconstruction time. 
    In the ICU and during the period of postoperative hospitaliza-
tion, the following variables in conjunction with five major 
morbidity endpoints were assessed and recorded: permanent 
stroke, renal dysfunction, hemostatic re-exploration, deep 
sternal wound infection, number of patients requiring 
prolonged ventilation (>48 h), as well as time to extubation and 
length of stay in the ICU [22]. For clarification, renal dysfunction 
was defined as acute postoperative renal insufficiency resulting 
in one or more of the following: (1) increase of Cr to >2.0 mg/dl, 
(2) ≥50% increase in Cr over preoperative baseline value, or (3) 
new requirement for dialysis. Tn–T was measured upon arrival 
at the ICU, and every 8 h until 24 h after surgery. Post  operative 
MI was defined as the occurrence of increase in Tn–T ≥ 0.5 ng/
ml (five times above the upper normal limit) and development 
of new pathologic Q wave or new left bundle branch block [23]. 
Decisions for extubation and discharge from ICU were made 
at the discretion of the ICU staff, consisting of cardiothoracic 
surgeons and anesthesiologists not aware of this study, 
according to the standard ICU protocols of our institution. 
Criteria for weaning from ventilator support included an 
appropriate sensorium, hemodynamic stability (CI > 2.2 L/
min/m
2; mean arterial pressure >60 mmHg; pulmonary artery 
diastolic pressure <20 mmHg; and no significant arrhythmias); 
PaO2 (arterial partial pressure of oxygen) > 100 mmHg with 
a FiO2 (fraction of inspired oxygen) = 0.4; minimal chest tube 
drainage; urine output 0.5 ml/kg/h; and temperature > 35.5°C. 
Discharge criteria from the ICU were as follows: stabilized 
patient’s clinical status without the need for ICU monitoring 
and care (which includes no further requirement for either 
inotropic or vasoactive agents except norepinephrine infusion 
less than 0.05 μg/kg/min), and no plan for further active 
intervention.
    Statistical analyses were performed using SPSS 12.0 (SPSS 
Inc., Chicago, IL, USA). All data are expressed as the number 
of patients or mean ± SD. Data between the groups were 
compared using the Chi-square test, Fisher’s exact test, or 
independent t-test as appropriate. A P value of less than 0.05 
was considered statistically significant. 
Results 
    Patients’ characteristics and operative data are shown in Table 
1. Patients’ characteristics including the existence of left main 
coronary artery disease and degree of coronary stenosis were all 
similar between the groups. There was, however, a trend toward 
higher incidence of recent MI in the statin group (24 vs. 34, P = 
0.088). Operative characteristics including the number of grafts 
and graft reconstruction time were also all similar.
    Postoperative data and biochemical data are shown in Tables 
Table 1. Patients’ Characteristics and Operative Data
Control 
(n = 72)
Statin 
(n = 72) P value
Age (years) 65 ± 10 66 ± 7 0.509
Gender (M/F) 45/27 50/22 0.379
Body surface area (m
2) 1.7 ± 0.2 1.7 ± 0.2 0.174
LVEF (%) 53 ± 11 52 ± 16 0.601
Diabetes  27 (38) 28 (39) 0.864
Hypertension  48 (67) 52 (72) 0.469
Chronic renal failure 8 (11)   8 (11) 1.000
Preoperative Cr (mg/dl) 1.0 ± 1.1 1.2 ± 1.5 0.701
Recent MI (< 1 month) 24 (33) 34 (47) 0.088
Preoperative medications
Nitrates 25 (35) 29 (40) 0.491
β-Blockers 50 (69) 53 (74) 0.580
Calcium channel blockers 33 (46) 36 (50) 0.617
RAS antagonists 24 (33) 24 (33) 1.000
Left main disease 12 (17)   8 (11) 0.370
Degree of stenosis (%)
LAD 85 ± 10      88 ± 8 0.323
LCx 88 ± 11 85 ± 12 0.419
RCA 83 ± 12 81 ± 13 0.611
Operative data
Operation time (min)    261 ± 56    259 ± 71 0.813
Number of grafts 3.3 ± 0.6 3.3 ± 0.6 0.688
Graft reconstruction time (min)       36 ± 5      36 ± 6 0.835
Values are mean ± standard deviation or number of patients (%). 
LVEF: left ventricular ejection fraction, Cr: creatinine, MI: myocar-
dial infarction, RAS: renin-angiotensin-system, LAD: left anterior 
descending, LCx: left circumflex, RCA: right coronary artery.139 www.ekja.org
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2 and 3, respectively. Among the major morbidity endpoints, 
there was a trend toward higher incidence of renal dysfunction 
in the control group, with significantly more patients requiring 
dialysis (Table 2). The hs-CRP values measured at various time 
points were all similar between the groups. Tn–T measured 
at predefined time points were also all similar, except at 24 h 
after surgery, when it was significantly lower in the statin group 
compared to the control group (Table 3).
Discussion 
    In the current trial addressing the effects of preoperative statin 
therapy on myocardial protection and morbidity endpoints in 
patients with elevated hs-CRP undergoing OPCAB, we could 
observe beneficial effects in terms of less Tn–T release and less 
incidence of new requirements for hemodialysis in patients 
treated with statins.
    As understanding of the pathophysiology of atherosclerosis 
has evolved, statins’ beneficial effects on the cardiovascular 
system came to include concept of the anti-inflammatory effect, 
improvement of endothelial dysfunction, increased nitric oxide 
bioavailability, antioxidant properties, plaque stabilization, 
inhibition of thrombosis, and smooth muscle proliferation, 
as well as the lipid-lowering effect [4,5,8]. According to recent 
AFCAPS/TexCAPS research [7], statin therapy successfully 
re  duced the incidence of MI, unstable angina, and coronary 
revascularization, regardless of cholesterol levels. Subsequently, 
statins are being widely prescribed for patients with a normal 
range of cholesterol levels to prevent acute coronary events. 
Several studies demonstrated that statin therapy is beneficial 
in patients undergoing variable cardiothoracic surgery [9]. 
Although conflicting results have been reported, many studies 
demonstrated that statins improve bypass graft patency rates, 
and reduce perioperative and long-term mortality rates, 
revascularization rates, and the number of postoperative com-
plications and hospital stays in patients undergoing on-pump 
CABG [9-15].
    The hs-CRP, a well-known marker of severity of coronary 
artery disease and a relevant predictor of outcome in patients 
with heart failure, has become a target of statin therapy 
because stains reduce CRP levels independently of their 
effects on cholesterol. Moreover, preoperative hs-CRP has 
been shown to be closely associated with early graft occlusion, 
cardiovascular events, and overall survival after CABG [17-
19]. Multivessel off-pump CABG requires mechanical heart 
displacement accompanied by cumulative, regional, and warm 
myocardial ischemia-reperfusion injury, and is associated 
with a considerable degree of inflammatory response [24-26]. 
Thus, patients with elevated hs-CRP undergoing CABG are 
considered to derive the most benefits from statin therapy, and 
we tried to assess the effect of statin therapy on myocardial 
protection and morbidity endpoints in patients with elevated 
hs-CRP undergoing off-pump CABG. 
    Of interest to note was that Tn–T level at 24 h after surgery was 
significantly lower in the patients who had taken any statins 
for at least one week before surgery despite their higher trend 
of recent preoperative MI history. We did not observe any 
significant increase in postoperative Tn–T values in both groups 
compared to each baseline value, which may be attributable 
to the high prevalence of recent MI (40%) and the already 
elevated baseline Tn–T levels in both groups. However, a trend 
could be seen in the control group toward a minor increase in 
Tn–T values as time passed, whereas it remained essentially 
Table 2. Postoperative Data
Control 
(n = 72)
Statin 
(n = 72)
P value
Major morbidity endpoints
Stroke   1 0 0.497
Hemostatic reoperation   0 2 0.248
Deep sternal wound infection   1  1 1.000
Renal dysfunction 14 6 0.054
Dialysis   8   1*  0.033
Ventilator care > 48 h   1 3 0.620
Postoperative MI   4 5 0.731
Length of ICU stay (days)    3.4 ± 3.7 2.9 ± 2.0 0.326
Length of postoperative
  hospital stay (days)
12.0 ± 8.0 14.1 ± 14.7 0.307
Mortality   0 1 0.497
Values are mean ± standard deviation or number of patients. *P < 
0.05 compared with control group. MI: myocardial infarction, ICU: 
intensive care unit.
Table 3. Postoperative Biochemical Data
Control (n = 72) Statin (n = 72) P value
hs-CRP (mg/dl)
Baseline   14.0 ± 16.8   11.8 ± 15.9 0.409
POD 1   7.5 ± 3.2   8.1 ± 3.1 0.349
POD 2 16.2 ± 6.1 17.0 ± 6.2 0.493
POD 3 14.5 ± 4.3 14.3 ± 6.1 0.899
Tn-T (ng/ml)
Baseline 0.4 ± 1.3 0.4 ± 1.4 0.907
0 hr 0.6 ± 1.5 0.4 ± 1.1 0.187
8 hr 0.6 ± 1.2 0.4 ± 1.3 0.193
16 hr 0.6 ± 1.0 0.4 ± 1.2 0.255
24 hr 0.5 ± 0.9   0.2 ± 0.2* 0.037
Values are mean ± standard deviation or number of patients. *P < 
0.05 compared with control group. hs-CRP: high sensitive C-reactive 
protein, Tn-T: troponin-T, POD: postoperative day.140 www.ekja.org
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the same until 16 hr postoperatively in the statin group, with a 
trend toward decreasing at 24 hr postoperatively. Considering 
the nearly absolute myocardial tissue specificity and the high 
predictive value of Tn–T for perioperative myocardial ischemia 
after CABG [26,27], our result indicates preoperative statin use 
could reduce the severity of postoperative myocardial necrosis 
and protect the myocardium after off-pump CABG in patients 
whose preoperative hs-CRP level is elevated.
    With regard to the major morbidity endpoints, we did not 
observe significant differences between the groups. This is in 
accordance with the results of a single center retrospective study 
on 1,706 patients undergoing CABG in which preoperative 
statin use was not associated with a reduction of perioperative 
MI, stroke, or prolonged ventilation [9]. However, our patients 
on statins displayed a trend toward lower renal dysfunction, 
and significantly fewer subjects required dialysis after surgery. 
This is supported by another retrospective cohort study of 
patients undergoing CABG, which demonstrated 50% lower 
incidence of new postoperative renal insufficiency, suggesting 
the renoprotective effect of preoperative statin therapy [28]. The 
relationship between dyslipidemia and renal function was well 
demonstrated, and other complex actions of statins, including 
restoration of endothelium-dependent NO production, anti-
inflammatory process, and improvement of microvascular 
cir  culation, are supposed to be the mechanisms of statins’ reno-
protective effects [3,9].
    Contrary to the result of a study that demonstrated reduced 
postoperative CRP concentrations following loading doses of 
atorvastatin in patients undergoing on-pump CABG [29], we 
found no relationship between preoperative statin therapy 
and postoperative hs-CRP levels. This may be attributable to 
heterogeneous types and dosages of statin therapy, as well as 
to the different nature of inflammatory response with regard to 
the degree and kinetics by the avoidance of cardiopulmonary 
bypass [22,30].
    The limitations of this study are as follows. Being a retro-
spective study, patients received statin therapy at the discretion 
of the attending physician and not according to randomization. 
Despite careful adjustment for potential confounders that 
might affect results, immeasurable confounding factors may 
still exist. Secondly, we defined the statin group as the patients 
who had taken statins for at least one week to allow for a steady 
state of drug concentrations according to the pharmacokinetic 
properties of the currently used statins; however, there is no 
confirmed duration of taking statins to show their effectiveness. 
Since the patients’ characteristics and operative data were all 
similar, and because all patients received standard anesthetic 
and surgical care according to institutional guidelines, the bias 
should be minimal. Thus, our results should provide novel 
evidence to support the beneficial effects of preoperative statin 
therapy in patients undergoing multivessel off-pump CABG. 
Based on these results, further prospective, randomized, and 
controlled trials should be performed to obtain definite con-
clusions.
    In conclusion, we observed beneficial effects of preoperative 
statin therapy for at least one week in terms of less myocardial 
enzyme release and fewer patients requiring dialysis following 
off-pump CABG in patients whose preoperative hs-CRP was 
elevated. 
References
1. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection 
Study Collaborative Group. MRC/BHF Heart Protection Study of 
cholesterol-lowering with simvastatin in 5963 people with diabetes: 
a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
2. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol 
EJ, et al. Early and sustained survival benefit associated with 
statin therapy at the time of percutaneous coronary intervention. 
Circulation 2002; 105: 691-6.
3. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton 
G. The effect of short term treatment with simvastatin on renal 
function in patients with peripheral arterial disease. Angiology 
2004; 55: 53-62.
4. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond 
lipid lowering: potential for clinical benefits. Int J Cardiol 2006; 109: 
7-15.
5. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. 
Circulation 2004; 109(23 Suppl 1): III39-43. 
6. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of 
statins. Pharmacol Ther 2003; 99: 95-112. 
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, 
et al. Primary prevention of acute coronary events with lovastatin 
in men and women with average cholesterol levels: results of 
AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis 
Prevention Study.  JAMA 1998; 279: 1615-22.
8. Paraskevas KI, Tzovaras AA, Briana DD, Mikhailidis DP. Emerging 
indications for statins: a pluripotent family of agents with several 
potential applications. Curr Pharm Des 2007; 13: 3622-36.
9. Paraskevas KI. Applications of statins in cardiothoracic surgery: 
more than just lipid-lowering. Eur J Cardiothorac Surg 2008; 33: 
377-90.
10.  Clark LL, Woolsen RF, Crawford FA Jr, Crumbley AJ III, Kratz JM. 
Preoperative statin treatment is associated with reduced post-
operative complications and morbidity in cardiac surgery patients: 
An 8-year retrospective study. Circulation 2004; 110(Suppl III): 506.
11.  Dotani MI, Elnicki DM, Jain AC, Gibson CM. Effect of preoperative 
statin therapy and cardiac outcomes after coronary artery bypass 
grafting. Am J Cardiol 2000; 86: 1128-30.
12.  Christenson JT. Preoperative lipid control with simvastatin 
reduces the risk for graft failure already 1year after myocardial 
revascularization. Cardiovasc Surg 2001; 9: 33-43.
13.  Dotani MI, Morise AP, Haque R, Jain AC, Gupta N, Gibson CM. 
Association between short-term simvastatin therapy before 
coronary artery bypass grafting and postoperative myocardial blood 141 www.ekja.org
Korean J Anesthesiol Song, et al.
flow as assessed by positron emission tomography. Am J Cardiol 
2003; 91: 1107-9.
14.  Collard CD, Body SC, Shernan SK, Wang S, Mangano DT. Pre-
operative statin therapy is associated with reduced cardiac mortality 
after coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 
2006; 132: 392-400.
15.  Lazar HL. Role of statin therapy in the coronary bypass patient. Ann 
Thorac Surg 2004; 78: 730-40.
16.  Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, 
Kastelein JJ, et al. JUPITER Study Group. Rosuvastatin to prevent 
vascular events in men and women with elevated C-reactive 
protein. N Engl J Med 2008; 359: 2195-207.
17.  Balciunas M, Bagdonaite L, Samalavicius R, Griskevicius L, 
Vuylsteke A. Pre-operative high sensitive C-reactive protein predicts 
cardiovascular events after coronary artery bypass grafting surgery: 
a prospective observational study. Ann Card Anaesth 2009; 12: 127-
32.
18.  Hedman A, Larsson PT, Alam M, Wallen NH, Nordlander R, Samad 
BA. CRP, IL-6 and endothelin-1 levels in patients undergoing 
coronary artery bypass grafting. Do preoperative inflammatory 
parameters predict early graft occlusion and late cardiovascular 
events? Int J Cardiol 2007; 120: 108-14.
19.  Kangasniemi OP, Biancari F, Luukkonen J, Vuorisalo S, Satta J, 
Pokela R, et al. Preoperative C-reactive protein is predictive of 
long-term outcome after coronary artery bypass surgery. Eur J 
Cardiothorac Surg 2006; 29: 983-5.
20.  Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et 
al. Measurement of C-reactive protein for the targeting of statin 
therapy in the primary prevention of acute coronary events. N Engl 
J Med 2001; 344: 1959-65.  
21.  Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, 
et al. C-reactive protein levels and outcomes after statin therapy. N 
Engl J Med 2005; 352: 20-8. 
22.  Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, 
Chen A, et al. The Society of Thoracic Surgeons: 30-day operative 
mortality and morbidity risk models. Ann Thorac Surg 2003; 75: 
1856-65. 
23.  Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et 
al. Universal definition of myocardial infarction. Circulation 2007; 
116: 2634-53.
24.  Raja SG, Berg GA. Impact of off-pump coronary artery bypass 
surgery on systemic inflammation: current best available evidence. 
J Card Surg 2007; 22: 445-55.
25.  Rastan AJ, Bittner HB, Gummert JF, Walther T, Schewick CV, 
Girdauskas E, et al. On-pump beating heart versus off-pump 
coronary artery bypass surgery-evidence of pump-induced 
myocardial injury. Eur J Cardiothorac Surg 2005; 27: 1057-64. 
26.  Han SH, Kim JH, Sim SE, Ham BM. Hemodynamic changes during 
off pump coronary artery bypass surgery. Korean J Anesthesiol 
2002; 43: 44-8.
27.  Holmvang L, Jurlander B, Rasmussen C, Thiis JJ, Grande P, 
Clemmensen P. Use of  biochemical markers of infarction for 
diagnosing perioperative myocardial infarction and early graft 
occlusion after coronary artery bypass surgery. Chest 2002; 121: 
103-11.
28.  Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD. 
Renoprotective effect of preoperative statins in coronary artery 
bypass grfating. Am J Cardiol 2007; 100: 442-4.
29.  Krivov N, Adler Z, Saloma R, Hawadie A, Azzam ZS. Targeting 
C-reactive protein using high-dose atorvastatin before coronary 
artery bypass graft surgery. Exp Clin Cardiol 2008; 13: 171-4.
30.  Tomic V, Russwurm S, Möller E, Claus RA, Blaess M, Brunkhorst 
F, et al. Transcriptomic and proteomic patterns of systemic 
inflammation in on–pump and off-pump coronary artery bypass 
grafting. Circulation 2005; 112: 2912-20.